Article
Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy.
Journal of medicinal chemistry - 14 Apr 2022
Tan Lun, Zhang Jifa, Wang Yuxi, Wang Xiye, Wang Yanyan, Zhang Zhixiong, Shuai Wen, Wang Guan, Chen Juncheng, Wang Chengdi, Ouyang Liang, Li Weimin
Abstract excerpt
Epidermal growth factor receptor (EGFR) is of great significance in mediating cell signaling transduction and tumor behaviors. Currently, third-generation inhibitors of EGFR, especially osimertinib, are at the clinical frontier for the treatment of EGFR-mutant non-small-cell lung cancer (NSCLC). Regrettably, the rapidly developing drug resistance caused by EGFR mutations and the compensatory mechanism have...
Topics
Join the communities discussing this publication.